Research programme: mTOR-protein-modulator therapeutics - Mount Tam/Isomerase

Drug Profile

Research programme: mTOR-protein-modulator therapeutics - Mount Tam/Isomerase

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mount Tam Biotechnologies
  • Developer Isomerase Therapeutics; Mount Tam Biotechnologies
  • Class
  • Mechanism of Action MTOR protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 09 Jan 2017 Early research in Undefined indication in USA
  • 09 Jan 2017 Mount Tam and Isomerase Therapeutics agree to develop mTOR-protein-modulator therapeutics for Undefined indication in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top